NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
At the end of last year, I decided to make an experiment for myself. I established a portfolio at Merrill Lynch with which I intended to break with my normal style and (1) only have a handful of posi...
US default risk has flatllined for weeks, market risk has leaked to record lows, and Treasury Bills have ‘behaved’… until now. The last two days have seen a sudden aggressive spik...
The goal of any investor is to either: Maximize returns given a fixed level of risk Minimize risk given a fixed level of desired returns Investors in the accumulation phase tend to fall under the firs...
Shares of Vertex (VRTX) are on the rise after the company reported positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have...
While it has not been completely “stealth-like” in nature, the evolution of the fixed income market over the last couple of years seems to have gone at least a little bit under the radar. Indeed, ...
Vertex Pharmaceuticals Incorporated (VRTX), a global biotechnology company yesterday announced positive results from its Phase 1 and 2 data for their cystic fibrosis treatment. The studies data showed...
U.S. President Donald Trump’s first major legislative move to overhaul the U.S. healthcare system had another setback after Republican leaders in the Senate abandoned the healthcare bill aiming to r...
GBP/USD Daily Timeframe Technical Outlook: Sterling has been trading within the confines of this ascending pitchfork formation extending off the 2016 low with the rally encountering confluence resi...
Support holding strong, dip-buyers still flying in at any moment of weakness. Yesterday was a sound day for the bulls from a technical standpoint. For one, the S&P 500, by a large margin, saw a hu...